Atrial fibrillation (AF) is the most common arrhythmia, ranging from 0.1% in patients< 55
years to> 9% in octogenarian patients. One important issue is represented by the 5-fold …

Atrial fibrillation (AF) is a major cause of ischaemic stroke. The majority of these strokes can
be prevented by treatment with oral anticoagulation therapy. The advent of non-vitamin K …

The landscape of stroke prevention in patients with atrial fibrillation (AF) is rapidly changing
after the introduction of nonvitamin K oral anticoagulants (NOACs) that are replacing in …

Aims Nonvitamin K antagonist oral anticoagulants (NOACs) are now available for the
prevention of stroke in patients with atrial fibrillation (AF) as an alternative to vitamin K …

Worldwide there is a tremendous need for affordable anticoagulants that do not require
monitoring. The advent of the non-warfarin oral anticoagulant drugs represents a major …

Introduction: Atrial fibrillation (AF) is associated with an increased risk of thromboembolic
events. Many patients with AF receive chronic anticoagulation, either with vitamin K …

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is associated
with substantial increases in the risk for stroke and systemic thromboembolism. With the …

The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

Aims The aim of the present meta-analysis was to evaluate the efficacy and safety of non-
vitamin K oral antagonists (NOACs) vs. vitamin K antagonists (VKAs) in elderly patients with …

Background—Novel oral anticoagulants (NOACs) have been proposed as alternatives to
vitamin K antagonists for the prevention of stroke and systemic embolism in patients with …